ANDA 214502, held by Zydus. Pimavanserin Tartrate.
As of Nov 22, 2026, ANDA 214502 (Pimavanserin), held by Zydus, was first approved by FDA on Jan 16, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2024 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| PimavanserinEQ 10MG BASE · tablet;oral | Pimavanserin Tartrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters